Rein Therapeutics Statistics
Total Valuation
RNTX has a market cap or net worth of $58.50 million. The enterprise value is $40.85 million.
| Market Cap | 58.50M |
| Enterprise Value | 40.85M |
Important Dates
The next estimated earnings date is Monday, April 14, 2025, after market close.
| Earnings Date | Apr 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RNTX has 21.67 million shares outstanding. The number of shares has increased by 201.87% in one year.
| Current Share Class | 21.67M |
| Shares Outstanding | 21.67M |
| Shares Change (YoY) | +201.87% |
| Shares Change (QoQ) | +8.80% |
| Owned by Insiders (%) | 1.18% |
| Owned by Institutions (%) | 26.23% |
| Float | 19.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.16 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.30
| Current Ratio | 3.30 |
| Quick Ratio | 3.12 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -54.95% and return on invested capital (ROIC) is -34.78%.
| Return on Equity (ROE) | -54.95% |
| Return on Assets (ROA) | -31.63% |
| Return on Invested Capital (ROIC) | -34.78% |
| Return on Capital Employed (ROCE) | -30.05% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.95M |
| Employee Count | 15 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -42.80% in the last 52 weeks. The beta is 2.23, so RNTX's price volatility has been higher than the market average.
| Beta (5Y) | 2.23 |
| 52-Week Price Change | -42.80% |
| 50-Day Moving Average | 2.16 |
| 200-Day Moving Average | 2.84 |
| Relative Strength Index (RSI) | 61.77 |
| Average Volume (20 Days) | 91,242 |
Short Selling Information
The latest short interest is 191,977, so 0.89% of the outstanding shares have been sold short.
| Short Interest | 191,977 |
| Short Previous Month | 194,299 |
| Short % of Shares Out | 0.89% |
| Short % of Float | 0.99% |
| Short Ratio (days to cover) | 1.95 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -29.62M |
| Pretax Income | n/a |
| Net Income | -29.24M |
| EBITDA | -29.50M |
| EBIT | -29.62M |
| Earnings Per Share (EPS) | -$2.13 |
Balance Sheet
| Cash & Cash Equivalents | 17.65M |
| Total Debt | n/a |
| Net Cash | 17.65M |
| Net Cash Per Share | $0.81 |
| Equity (Book Value) | 95.23M |
| Book Value Per Share | 2.32 |
| Working Capital | 13.03M |
Cash Flow
| Operating Cash Flow | -27.87M |
| Capital Expenditures | n/a |
| Free Cash Flow | -27.87M |
| FCF Per Share | -$1.29 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RNTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -201.87% |
| Shareholder Yield | -201.87% |
| Earnings Yield | -49.99% |
| FCF Yield | -47.64% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -14.89% |
Stock Splits
The last stock split was on November 11, 2022. It was a reverse split with a ratio of 0.05:1.
| Last Split Date | Nov 11, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.05:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |